What Happened?
South San Francisco, CA-based Neuron-Therapeutics Appointed Tim Kutzkey as Chief Executive Officer
About the Company
Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company`s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders. For more information about Neurona visit our website.
About the Person
Dr. Tim Kutzkey serves as the interim Chief Executive Officer at Neurona. He is currently a Partner at The Column Group (TCG). Since joining TCG in 2007, Dr. Kutzkey has contributed to the conception, formation, and management of many of the firm`s portfolio companies. In addition to Neurona, he is currently a Board Director of Peloton Therapeutics, a company he launched in 2010 as the President and CEO. Dr. Kutzkey also serves on the Board of Directors of Nurix, Carmot Therapeutics, and Kallyope. Dr. Kutzkey was formerly a scientist at KAI Pharmaceuticals, focused on the discovery and development of selective protein kinase C inhibitors. Prior to KAI, he worked at UC Berkeley as a graduate student and postdoctoral scholar in the lab of Dr. Robert Tjian, completing his PhD in 2005. Dr. Kutzkey was previously educated at Stanford University.
Info Source
Press Release
Short Profile